Unilife CEO resigns from drug delivery device company amid post-Amgen deal reorg

On the heels of a much-needed alliance with Amgen ($AMGN) which gave it a cash lifeline, drug delivery device specialist Unilife ($UNIS) has entered restructure mode. The struggling York, PA, company announced that its CEO, Alan Shortall, and COO, Dr. Ramin Mojdeh, have resigned. Executive search firm Heidrick & Struggles will be searching for a permanent CEO, while senior vice president and general counsel John Ryan takes the helm as interim CEO. He will be helped by a new executive leadership team. In addition, the company now has two business units: Wearable and Auto Injectors and Prefilled Syringes. More

Suggested Articles

Millions of tests are urgently needed as the virus keeps communities across the country in lockdown and hospitals are overwhelmed with patients.

The FDA granted its first emergency authorization for a rapid antibody blood test for COVID-19 developed by Cellex.

The ultimate goal is to move as many patients as possible out of the clinic that don’t need immediate, critical care.